In a cohort of 25 patients treated with AMG 510 confirmed partial responses were observed in 3 patients who had appendiceal cancer, melanoma, and endometrial cancer, respectively. Thirteen patients achieved stable disease and included 6 patients with pancreatic cancer, 2 with appendiceal cancer, 1 with ampullary cancer, and 1 with bile duct cancer, 1 with endometrial cancer, 1 with sinonasal cancer, and 1 with unknown primary cancer. Read more . . .